Opinion
Video
Navigating Cost Considerations in Treatment Selection of mCRC Agents
Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.
Video Player is loading.
Video content above is prompted by the following:
- What are the key payer-related challenges (eg, step edits, prior authorizations) that impact access to third-line therapies for patients with mCRC?
- How do payer requirements influence treatment sequencing and decision-making in the third-line setting?
- How do the costs associated with adverse events across the different third-line treatments (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab) influence treatment selection?
Related Videos
Pharmacist-Led Strategies for Adverse Event Management in mCRC
The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease
Role of Patients’ Education in Uncomplicated UTIs
Overcoming Key Operational Challenges in Integrating Bispecific Therapies
Understanding CGM Metrics
Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
CGM vs Traditional Monitoring
Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations
Related Content
